Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2021

27.08.2020 | Original Article

Hiatal Hernia Associated with Higher Odds of Dysplasia in Patients with Barrett’s Esophagus

verfasst von: Joshua Y. Kwon, Alex M. Kesler, Herbert C. Wolfsen, Kenneth R. DeVault, Paul T. Kröner

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with Barrett’s esophagus (BE) are more likely to have associated hiatal hernia (HH) compared to the general population. Studies show that HH are typically longer and wider in patients with BE.

Aims

To determine whether patients with HH have associated increased odds of coexistence of BE by examining inpatient prevalence, as well as determining other inpatient outcomes.

Methods

This was a case–control study using the NIS 2016, the largest public inpatient database in the USA. All patients with ICD10CM codes for BE were included. None were excluded. The primary outcome was determining the association between BE and HH in hospitalized patients, stratified by grade of dysplasia. Secondary outcomes included measuring use of endoscopic ablation in patients with BE and HH compared to patients with BE and no HH, determining the degree of association between HH and esophagitis in patients with or without BE, as well as the association between esophagitis and dysplasia in patients with BE and HH.

Results

A total of 118,750 patients with BE were identified, of which 24,030 had associated HH. Adjusted odds of having associated BE in patients with HH was 10.9 (p < 0.01) compared to patients without HH. Patients with HH also displayed significantly higher odds of both low-grade dysplasia (aOR 34.5, p < 0.01) and high-grade dysplasia (aOR 14.7, p < 0.01). For secondary outcomes, the odds of undergoing ablation for BE was higher 4.77 (p < 0.01) in patients with HH.

Conclusions

Patients with HH have significantly higher odds of having associated BE, regardless of the level of dysplasia. Furthermore, the odds of undergoing ablation are much higher, likely reflecting higher odds of dysplasia. This highlights the importance of BE in patients with HH, and potentially consider these patients as higher risk.
Literatur
1.
Zurück zum Zitat Sjogren RW, Johnson LF. Barrett’s esophagus: a review. Am J Med. 1983;74:313–321.CrossRef Sjogren RW, Johnson LF. Barrett’s esophagus: a review. Am J Med. 1983;74:313–321.CrossRef
2.
Zurück zum Zitat Spechler SJ, Goyal RK. Barrett’s esophagus. N Eng J Med. 1986;315:362–371.CrossRef Spechler SJ, Goyal RK. Barrett’s esophagus. N Eng J Med. 1986;315:362–371.CrossRef
3.
Zurück zum Zitat Kahrilas PJ. Gastroesophageal Reflux Dis Jama. 1996;276:983–988. Kahrilas PJ. Gastroesophageal Reflux Dis Jama. 1996;276:983–988.
4.
Zurück zum Zitat Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol. 2005;3:1–10.CrossRef Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol. 2005;3:1–10.CrossRef
5.
Zurück zum Zitat Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41.CrossRef Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41.CrossRef
6.
Zurück zum Zitat Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Gastroenterology. 2012;142:744–753.CrossRef Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Gastroenterology. 2012;142:744–753.CrossRef
7.
Zurück zum Zitat Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAmA. 2011;306:410–419.CrossRef Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAmA. 2011;306:410–419.CrossRef
8.
Zurück zum Zitat Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRef Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRef
9.
Zurück zum Zitat Sharma P, Morales T, Sampliner R. Short segment Barrett’s esophagus—the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998;93:1033–1036.CrossRef Sharma P, Morales T, Sampliner R. Short segment Barrett’s esophagus—the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998;93:1033–1036.CrossRef
10.
Zurück zum Zitat Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett’s esophagus. Digest Dis Sci. 2002;47:256–264.CrossRef Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett’s esophagus. Digest Dis Sci. 2002;47:256–264.CrossRef
11.
Zurück zum Zitat Allison P, Johnstone A. The oesophagus lined with gastric mucous membrane. Thorax. 1953;8:87.CrossRef Allison P, Johnstone A. The oesophagus lined with gastric mucous membrane. Thorax. 1953;8:87.CrossRef
12.
Zurück zum Zitat Burgess J, Payne W, Andersen H, Weiland L, Carlson H. Barrett esophagus: the columnar-epithelial-lined lower esophagus. Mayo Clinic Proceedings; 1971. p. 728. Burgess J, Payne W, Andersen H, Weiland L, Carlson H. Barrett esophagus: the columnar-epithelial-lined lower esophagus. Mayo Clinic Proceedings; 1971. p. 728.
13.
Zurück zum Zitat Naef A, Savary M. Conservative operations for peptic esophagitis with stenosis in columnar-lined lower esophagus. The Annals of thoracic surgery. 1972;13:543–551.CrossRef Naef A, Savary M. Conservative operations for peptic esophagitis with stenosis in columnar-lined lower esophagus. The Annals of thoracic surgery. 1972;13:543–551.CrossRef
14.
Zurück zum Zitat Borrie J, Goldwater L. Columnar cell-lined esophagus: assessment of etiology and treatment: A 22 year experience. The Journal of thoracic and cardiovascular surgery. 1976;71:825–834.CrossRef Borrie J, Goldwater L. Columnar cell-lined esophagus: assessment of etiology and treatment: A 22 year experience. The Journal of thoracic and cardiovascular surgery. 1976;71:825–834.CrossRef
15.
Zurück zum Zitat Cameron AJ. Barrett’s esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999;94:2054–2059.CrossRef Cameron AJ. Barrett’s esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999;94:2054–2059.CrossRef
16.
Zurück zum Zitat Andrici J, Tio M, Cox MR, Eslick GD. Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol. 2013;28:415–431.CrossRef Andrici J, Tio M, Cox MR, Eslick GD. Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol. 2013;28:415–431.CrossRef
17.
Zurück zum Zitat Wakelin DE, Al-Mutawa T, Wendel C, Green C, Garewal HS, Fass R. A predictive model for length of Barrett’s esophagus with hiatal hernia length and duration of esophageal acid exposure. Gastrointest Endosc. 2003;58:350–355.CrossRef Wakelin DE, Al-Mutawa T, Wendel C, Green C, Garewal HS, Fass R. A predictive model for length of Barrett’s esophagus with hiatal hernia length and duration of esophageal acid exposure. Gastrointest Endosc. 2003;58:350–355.CrossRef
18.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.CrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.CrossRef
19.
Zurück zum Zitat Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRef Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRef
20.
Zurück zum Zitat Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N. Engl. J. Med. 2011;365:1375–1383.CrossRef Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N. Engl. J. Med. 2011;365:1375–1383.CrossRef
21.
Zurück zum Zitat Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004;99:1657–1666.CrossRef Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004;99:1657–1666.CrossRef
22.
Zurück zum Zitat Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97:1930–1936.CrossRef Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97:1930–1936.CrossRef
23.
Zurück zum Zitat Mittal RK, Balaban DH. The esophagogastric junction. N. Engl. J. Med. 1997;336:924–932.CrossRef Mittal RK, Balaban DH. The esophagogastric junction. N. Engl. J. Med. 1997;336:924–932.CrossRef
24.
Zurück zum Zitat Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology. 1987;92:130–135.CrossRef Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology. 1987;92:130–135.CrossRef
25.
Zurück zum Zitat Crumplin M, Stol D, Murphy G, Collis J. The pattern of bile salt reflux and acid secretion in sliding hiatal hernia. Br J Surg. 1974;61:611–616.CrossRef Crumplin M, Stol D, Murphy G, Collis J. The pattern of bile salt reflux and acid secretion in sliding hiatal hernia. Br J Surg. 1974;61:611–616.CrossRef
26.
Zurück zum Zitat Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett’s esophagus. Gastroenterology. 1994;107:747–754.CrossRef Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett’s esophagus. Gastroenterology. 1994;107:747–754.CrossRef
27.
Zurück zum Zitat Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359.e2.PubMed Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359.e2.PubMed
28.
Zurück zum Zitat Playford R. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut. 2006;55:442.CrossRef Playford R. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut. 2006;55:442.CrossRef
29.
Zurück zum Zitat Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:191–198.CrossRef Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:191–198.CrossRef
30.
Zurück zum Zitat van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011;60:765–773.CrossRef van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011;60:765–773.CrossRef
31.
Zurück zum Zitat Korst RJ, Santana-Joseph S, Rutledge JR, et al. Effect of hiatal hernia size and columnar segment length on the success of radiofrequency ablation for Barrett’s esophagus: a single-center, phase II clinical trial. J Thorac Cardiovascul Surg. 2011;142:1168–1173.CrossRef Korst RJ, Santana-Joseph S, Rutledge JR, et al. Effect of hiatal hernia size and columnar segment length on the success of radiofrequency ablation for Barrett’s esophagus: a single-center, phase II clinical trial. J Thorac Cardiovascul Surg. 2011;142:1168–1173.CrossRef
32.
Zurück zum Zitat Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143:576–581.CrossRef Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143:576–581.CrossRef
33.
Zurück zum Zitat Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci. 2012;57:2625–2632.CrossRef Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci. 2012;57:2625–2632.CrossRef
34.
Zurück zum Zitat Akiyama J, Roorda A, Triadafilopoulos G. Managing Barrett’s esophagus with radiofrequency ablation. Gastroenterol Rep. 2013;1:95–104.CrossRef Akiyama J, Roorda A, Triadafilopoulos G. Managing Barrett’s esophagus with radiofrequency ablation. Gastroenterol Rep. 2013;1:95–104.CrossRef
Metadaten
Titel
Hiatal Hernia Associated with Higher Odds of Dysplasia in Patients with Barrett’s Esophagus
verfasst von
Joshua Y. Kwon
Alex M. Kesler
Herbert C. Wolfsen
Kenneth R. DeVault
Paul T. Kröner
Publikationsdatum
27.08.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06559-x

Weitere Artikel der Ausgabe 8/2021

Digestive Diseases and Sciences 8/2021 Zur Ausgabe

PROFILES AND PERSPECTIVES

DDS Profile: Deborah D. Proctor, MD

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.